May 20 | 2021 2cureX’s clinical partner, University Hospital Vejle, presents positive results of the IndiTreat®-guided clinical trial in third line metastatic colorectal cancer at the ASCO 2021 Annual Meeting Read more
May 11 | 2021 Teckningsoptioner av serie TO1 tecknades till cirka 96,75 procent och 2cureX AB tillförs cirka 31,40 MSEK Read more
May 11 | 2021 Warrants of series TO1 were subscribed to approximately 96.75 percent and 2cureX AB receives approximately SEK 31.40 million. Read more
May 5 | 2021 Sista dag för handel med teckningsoptionerna av serie TO1 i 2cureX AB är idag, den 5 maj 2021 Read more
April 26 | 2021 2cureX styrelse och ledning nyttjar samtliga innehavda teckningsoptioner av serie TO1 för 6,04 MSEK Read more
April 26 | 2021 Board and management of 2cureX exercise all held warrants of series TO1 for SEK 6.04 million Read more
April 24 | 2021 Correction of “Notice to attend the Annual General Meeting of 2cureX AB” issued on 23[rd] April 2021. Read more
April 24 | 2021 Korrektion till ”Kallelse till årsstämma i 2cureX AB” utfärdad den 23 april 2021. Read more